innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma
Company profile
Ticker
IPHA, IPHYF
Exchange
Website
CEO
Mondher Mahjoubi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Innate Pharma, SA
SEC CIK
IPHA stock data
Latest filings (excl ownership)
6-K
Summary of Consolidated Financial Statements and Notes
21 Mar 24
6-K
Innate Pharma reports Full Year 2023 Financial Results and Business Update
21 Mar 24
6-K
Innate Pharma Announces Its Participation To Upcoming Investor Conference
19 Mar 24
6-K
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results
14 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Current report (foreign)
6 Mar 24
6-K
Innate Pharma Announces Its Participation To Upcoming Investor Conference
21 Feb 24
6-K
Current report (foreign)
6 Feb 24
424B5
Prospectus supplement for primary offering
6 Feb 24
EFFECT
Notice of effectiveness
17 Jan 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
9.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 820.34 mm |
Total shares | 7.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bpifrance Participations | 7.19 mm | $15.81 mm |
Optiver Holding B.V. | 190.22 k | $481.25 mm |
Millennium Management | 46.97 k | $118.84 mm |
MS Morgan Stanley | 44.95 k | $113.73 mm |
Exchange Traded Concepts | 35.00 k | $88.55 mm |
Steward Partners Investment Advisory | 500.00 | $1.27 mm |
BCS Barclays | 412.00 | $1.00 k |
Rhumbline Advisers | 205.00 | $518.00 k |
UBS UBS Group AG - Registered Shares | 146.00 | $369.00 k |
Proequities | 0.00 | $0.00 |
News
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
22 Mar 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Innate Pharma FY EPS $(0.10) Up From $(0.75) YoY, Sales $66.35M Up From $58.87M YoY
21 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
11 Mar 24
Innate Pharma Announces That It Will Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At AACR 2024
6 Mar 24
Press releases
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
21 Mar 24
Innate Pharma Announces Its Participation to Upcoming Investor Conference
19 Mar 24
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
14 Mar 24
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
6 Mar 24
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma
6 Mar 24